Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Current Leases (2022 - 2025)

Entrada Therapeutics has reported Current Leases over the past 4 years, most recently at $4.1 million for Q4 2025.

  • Quarterly results put Current Leases at $4.1 million for Q4 2025, down 45.26% from a year ago — trailing twelve months through Dec 2025 was $4.1 million (down 45.26% YoY), and the annual figure for FY2025 was $4.1 million, down 45.26%.
  • Current Leases for Q4 2025 was $4.1 million at Entrada Therapeutics, down from $4.4 million in the prior quarter.
  • Over the last five years, Current Leases for TRDA hit a ceiling of $8.6 million in Q2 2024 and a floor of $4.1 million in Q4 2025.
  • Median Current Leases over the past 4 years was $7.6 million (2024), compared with a mean of $7.2 million.
  • Biggest five-year swings in Current Leases: rose 16.87% in 2024 and later crashed 45.26% in 2025.
  • Entrada Therapeutics' Current Leases stood at $8.4 million in 2022, then fell by 5.91% to $7.9 million in 2023, then fell by 4.43% to $7.6 million in 2024, then tumbled by 45.26% to $4.1 million in 2025.
  • The last three reported values for Current Leases were $4.1 million (Q4 2025), $4.4 million (Q3 2025), and $5.5 million (Q2 2025) per Business Quant data.